Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2007

European Medicines Agency Recommends Approval of Liver Cancer Drug

  • Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals report that an advisory panel to the European Commission issued a positive review of the companies’ liver cancer drug for approval.

    The European Committee for Medicinal Products for Human Use recommended that Nexavar be granted marketing authorization for the treatment of patients with hepatocellular carcinoma.

    Nexavar is under priority review at the FDA. The drug is already marketed in over 50 countries including the U.S. for the treatment of advanced kidney cancer, according to the firms.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »